Digest Network Come funziona
Network
/
Società
Ge
Non verificato

Genmab A/S

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

26 comunicati stampa

Guarda tutti i comunicati
12/12/2025
Mercato azionario
Oncologia
Salute
Medicina - Varie
Farmaceutica
Cardiologia
Biotecnologia
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
Fonte
Genmab A/S
Emittente
Business Wire
1.00
0
08/12/2025
Eventi
Fiere
Industria
Oncologia
Salute
Medicina - Varie
Farmaceutica
Cardiologia
Biotecnologia
Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)
Fonte
Genmab A/S
Emittente
Business Wire
1.00
0
07/12/2025
Industria
Oncologia
Salute
Medicina - Varie
Farmaceutica
Cardiologia
Biotecnologia
Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma
Fonte
Genmab A/S
Emittente
Business Wire
1.00
0
06/12/2025
Eventi
Industria
Scienza
Cardiologia
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)
Fonte
Genmab A/S
Emittente
Business Wire
1.00
0
18/11/2025
Igiene alimentare
Salute
Medicina - Varie
Sanità
Farmaceutica
Biotecnologia
Industria
Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma
Fonte
Genmab A/S
Emittente
Business Wire
1.00
0
03/11/2025
Scienza
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Medicina - Varie
Industria
Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting
Fonte
Genmab A/S
Emittente
Business Wire
1.00
0
29/09/2025
Biotecnologia
Salute
Oncologia
Medicina - Varie
Mercato azionario
Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model
Fonte
Genmab A/S
Emittente
Business Wire
1.00
0
03/09/2025
Oncologia
Salute
Medicina - Varie
Farmaceutica
Cardiologia
Biotecnologia
Eventi
Industria
Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Fonte
Genmab A/S
Emittente
Business Wire
1.00
0
26/08/2025
Oncologia
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Industria
Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC)
Fonte
Genmab A/S
Emittente
Business Wire
1.00
0
02/06/2025
Biotecnologia
Sanità
Salute
Medicina - Varie
Oncologia
Eventi
Industria
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial
Fonte
Genmab A/S
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0